Pfizer, Inc. (PFE) Expected to Announce Quarterly Sales of $13.16 Billion
Analysts expect Pfizer, Inc. (NYSE:PFE) to post $13.16 billion in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Pfizer’s earnings, with the lowest sales estimate coming in at $13.02 billion and the highest estimate coming in at $13.41 billion. Pfizer posted sales of $13.05 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 0.8%. The company is expected to announce its next quarterly earnings results on Tuesday, November 7th.
On average, analysts expect that Pfizer will report full year sales of $13.16 billion for the current financial year, with estimates ranging from $52.21 billion to $53.27 billion. For the next year, analysts anticipate that the firm will post sales of $53.91 billion per share, with estimates ranging from $52.81 billion to $54.78 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Pfizer.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. The company had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter last year, the company earned $0.64 EPS. The company’s quarterly revenue was down 1.9% on a year-over-year basis.
A number of equities research analysts have recently issued reports on PFE shares. Cowen and Company set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Monday, July 10th. Barclays PLC restated a “buy” rating and set a $38.00 price objective on shares of Pfizer in a report on Wednesday, May 3rd. Sanford C. Bernstein restated a “buy” rating and set a $37.00 price objective on shares of Pfizer in a report on Wednesday, May 3rd. UBS AG restated a “buy” rating and set a $38.00 price objective on shares of Pfizer in a report on Monday, July 31st. Finally, Jefferies Group LLC restated a “hold” rating and set a $35.00 price objective (up previously from $34.00) on shares of Pfizer in a report on Friday, July 14th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $37.61.
COPYRIGHT VIOLATION NOTICE: “Pfizer, Inc. (PFE) Expected to Announce Quarterly Sales of $13.16 Billion” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/15/pfizer-inc-pfe-expected-to-announce-quarterly-sales-of-13-16-billion.html.
In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the company. Asset Planning Services Ltd. increased its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares during the period. Shine Investment Advisory Services Inc. bought a new position in shares of Pfizer during the second quarter valued at about $102,000. Mckinley Capital Management LLC Delaware bought a new position in shares of Pfizer during the second quarter valued at about $103,000. D. Scott Neal Inc. increased its position in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the period. Finally, Orrstown Financial Services Inc. increased its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares during the period. Hedge funds and other institutional investors own 69.94% of the company’s stock.
Shares of Pfizer (NYSE:PFE) opened at 33.31 on Tuesday. The company has a market cap of $198.79 billion, a P/E ratio of 24.37 and a beta of 1.00. Pfizer has a 12 month low of $29.83 and a 12 month high of $35.38. The firm has a 50 day moving average price of $33.38 and a 200-day moving average price of $33.35.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 3.84%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s payout ratio is presently 94.12%.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.